Join this Featured Workgroup!
Elite Investors

This group is for elite investors and traders that are dedicated to participating in an active community that wants to learn from each other, share their research, and work together to do deep analysis of securities. The moderator of this group taught securities analysis at UCLA and is dedicated to helping other investors improve their abilities.

In this private group, membership is restricted and regular contributions are required. Any member not contributing on a regular basis will be removed to make room for a new member.

In your application messsage, please share your background and what you can contribute to the group.



Company Overview and News

8
Novo Nordisk Buys Ziylo to Develop Glucose Responsive Insulin

22h zacks
Novo Nordisk A/S (NVO - Free Report) announced that it has acquired all of the shares of Ziylo Ltd. Ziylo is a University of Bristol spin-out company based at Unit DX science incubator in the United Kingdom. Total payments under the agreement could exceed $800 million upon the achievement of certain development, regulatory and sales milestones by Novo Nordisk.
VRTX CELGZ GILD CELG UTX URBN

2
Top 5 ROE Picks on Optimism Over Resolution of Trade Dispute

2018-08-20 zacks
The U.S. equity markets shrugged off the brief spell of volatility triggered by the plunging Turkish lira and continued its uptrend, thanks to the renewed optimism relating to the probable resolution of the trade dispute with China. The communist country announced that it will send vice commerce minister Wang Shouwen to the United States in late August to initiate trade talks at the lower rungs — the first official exchange in two months — showing signs of possible patch-up of the trade hostilities between the nations.
NRGEO NRG CBG CELGZ CELG PGR CBRE CE

3
U.S. health secretary says agency has power to eliminate drug rebates

2018-08-20 reuters
WASHINGTON (Reuters) - U.S. Health and Human Services Secretary Alex Azar said it was within his agency’s power to eliminate rebates on prescription drug purchases, a key element of the Trump administration’s plan to lower prescription medicine costs.
PFZ CELGZ CELG 500680 PFE PFIZER

23
Spring Bank Pharmaceuticals, Inc. Appoints Scott Smith to its Board of Directors

2018-08-16 globenewswire - 2
HOPKINTON, Mass., Aug. 16, 2018 (GLOBE NEWSWIRE) -- Spring Bank Pharmaceuticals, Inc. (NASDAQ:SBPH), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of viral infections, inflammatory diseases and certain cancers, today announced that it has added Scott Smith as an independent member of its Board of Directors to replace Jonathan Bates, who is stepping down from his role as a director after a long period of service to the company.
CELGZ SBPH CELG TTNP

22
Geron's Growth Depends on Continuation of Imetelstat Studies

2018-08-15 zacks - 7
On Aug 14, we issued an updated research report on Geron Corporation (GERN - Free Report) . This developmental stage biopharmaceutical company, based in Cambridge, MA, is focused on the development of first-in-class therapeutic products with its patented core technology, telomerase, for the treatment of cancer.
XLRN CELGZ GERN JNJ CELG

3
Is The Bottom In For Celgene?

2018-08-14 seekingalpha - 1
Celgene Corporation (CELG) has had a less than ideal past 10 months. Hitting highs in early October 2017 of $147.17, the stock fell to $74.13 in May 2018. A 50 percent drop, or a 50 percent pop, is standard for many of the smaller biotechs I cover, but not normally, the domain of a $60B biopharmaceutical giant like CELG. A lot of the factors that led to the drop of CELG are in the past now, and the focus of this article isn't to dwell on those.
CELGZ 524816 ARNA RDY NATCOPHARM CELG RCPT MS

5
Ligand (LGND) Proposes to Buy U.K.'s Drug Discovery Biotech

2018-08-13 zacks
Ligand Pharmaceuticals, Inc. (LGND - Free Report) has announced that it will acquire U.K.’s structure-based drug discovery biotechnology company, Vernalis, for a purchase consideration of approximately $43 million. The transaction requires the company to buy all the issued and to be issued shares of Vernalis through a UK scheme of arrangement, subject to approvals of Vernalis’ shareholders.
FOX CELGZ GILD LMHA ILMN LMHB LGNDZ LGNZZ CELG LGND LGNYZ LGNXZ FOXA LM

5
Eloxx Pharmaceuticals' (ELOX) CEO Robert Ward on Q2 2018 Results - Earnings Call Transcript

2018-08-12 seekingalpha - 2
Good afternoon, everyone, and welcome to Eloxx Pharmaceuticals Second Quarter 2018 Earnings Webcast and Conference Call. Today’s call is being recorded. At this time, I would like to turn the call over to Ms. Barbara Ryan, Eloxx’s Investor Relations Officer. Please begin.
CELGZ CELG MDCO ELOX RDUS DTEGF DTEGY SVOND

4
BeiGene Reports Second Quarter 2018 Financial Results

2018-08-09 globenewswire
CAMBRIDGE, Mass. and BEIJING, China, Aug. 09, 2018 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative molecularly-targeted and immuno-oncology drugs for the treatment of cancer, today reported recent business highlights and financial results for the second quarter and first half of 2018.
CICHY CELGZ MRTX CELG BGNE CICHF CCB 0939

2
Musk's Ambitions Rekindle Celgene Privatization Musings at RBC - Bloomberg

2018-08-08 bloomberg
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.
CELGZ CELG

2
BeiGene Announces Closing of Its HK$7.08 billion (US$903 million) Hong Kong Initial Public Offering and Global Offering

2018-08-08 globenewswire
BEIJING, China and CAMBRIDGE, Mass., Aug. 08, 2018 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ:BGNE), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative molecularly-targeted and immuno-oncology drugs for the treatment of cancer, today announced the closing of its previously announced Hong Kong initial public offering and global offering (the “Offering”) of 65,600,000 ordinary shares, par value $0.
DB CELGZ CELG BGNE MS

8
Prothena (PRTA) Q2 Earnings Lag Estimates, Pipeline in Focus

2018-08-08 zacks
Prothena Corporation plc (PRTA - Free Report) reported a loss of 98 cents per share for the second quarter of 2018, wider than the Zacks Consensus Estimate of a loss of 88 cents and the year-ago loss of 46 cents.
ELY CELGZ GILD ICFI CELG

11
Mirati Therapeutics: Innovating Stellar Molecules For Cancer Treatment

2018-08-07 seekingalpha
Mirati is a gift that keeps on giving, as the company logged astronomical profits for shareholders.
BRK.A CELGZ AZN MRTX CELG BGNE NVS LLY BMY

5
bluebird (BLUE) Q2 Loss Wider Than Expected, Revenues Miss

2018-08-03 zacks
bluebird bio, Inc. (BLUE - Free Report) reported a loss of $2.91 per share, much wider than the Zacks Consensus Estimate of a loss of $2.30 and the year-ago loss of $1.73. The wider-than-expected loss was due to higher research & development (R&D) and general & administrative (G&A) expenses on lower revenues.
CELGZ BLUE CELG NVS BLUE

2
Regeneron Pharmaceuticals (REGN) Jumps: Stock Rises 7%

2018-08-03 zacks
Regeneron Pharmaceuticals, Inc. (REGN - Free Report) was a big mover last session, as the company saw its shares rise 7% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. This continues the recent uptrend for the company—as the stock is now up 12.2% in the past one-month time frame.
REGN CY CELGZ CELG

Related Articles

REPH: Recro Pharma Analysis and Research Report

2018-08-20 - Asif

Overview Recro Pharma is a specialty pharmaceutical company that operates through two business divisions: an Acute Care division and a revenue-generating CDMO division. Each of these divisions are deemed to be reportable segments for financial reporting purposes. The company's Acute Care segment is primarily focused on developing and commercializing innovative products for hospital and related acute care settings. The company's lead product candidate is a proprietary injectable form of meloxicam, a long-acting preferential COX-2 inhibitor. IV meloxicam has successfully completed three Phase III clinical trials for the management of moderate to severe pain, consisting of two pivotal efficacy trials and a large double-blind Phase III safety trial, as well as other safety studies. Overall, the total new drug application, or NDA, program included over 1,400 patients. In late July 2017, the company submitted a NDA to the U.S. Food and Drug Administration, or FDA, for IV meloxicam...

ACHN: Achillion Pharmaceuticals Analysis and Research Report

2018-08-20 - Asif

Overview Achillion Pharmaceuticals is a clinical-stage biopharmaceutical company focused on advancing its oral factor D inhibitors into late-stage development and commercialization. Each of the drug candidates in its oral factor D portfolio was discovered in its laboratories and is wholly owned by it. Achillion Pharmaceuticals is focusing its drug development activities on alternative pathway-mediated, rare diseases where there are no approved therapies or where existing therapies are inadequate for patients. To advance its investigational drugs into phase III and commercialization, the company plan to work closely with key stakeholders including patients, payors, regulators and healthcare professionals. The company's first-generation factor D inhibitor, ACH-4471, has demonstrated preliminary clinical proof-of-concept in patients with C3 glomerulopathy, or C3G, a disease affecting the kidney, and paroxysmal nocturnal hemoglobinuria, or PNH, a blood disorder, and has advanced...

BTE: Baytex Energy Trust Analysis and Research Report

2018-08-20 - Asif

General Baytex Energy Corp. was incorporated on October 22, 2010 pursuant to the provisions of the ABCA. Baytex is the successor to the business of Baytex Energy Trust, which was transitioned to Baytex on December 31, 2010. Inter-Corporate Relationships The following table provides the name, the percentage of voting securities owned by it and the jurisdiction of incorporation, continuance, formation or organization of its material subsidiaries either, direct and indirect, as at the date hereof. ||Percentage of voting securities (directly or indirectly)|Jurisdiction of Incorporation/Formation| | ------------ | ------------: | :------------: | |Baytex Energy Ltd.|100%|Alberta| |Baytex Energy USA, Inc.|100%|Delaware| |Baytex Energy Partnership|100%|Alberta| Organizational Structure The following simplified diagram shows the inter-corporate relationships among it and its material subsidiaries as of the date hereof. <img src="https://www.sec.gov/A...

CUSIP: 151020112